Cumulus Oncology Ltd has appointed Manuel Aivado, a haematologist and oncologist, to its board and Brian Jones, experienced in small molecule drug discovery, as a scientific advisor. In recent years Dr Aivado played a key role in six new drug approvals, including four in oncology, and has a strong track record in clinical development strategies as well as business management.
Dr Jones will support the progression of Cumulus’ portfolio as well as improving the identification of novel asset acquisition targets. The appointments come as Cumulus makes progress on several programmes. It expects to share data updates by the end of 2025, including in vivo proof-of-concept results in oncology and inflammation indications.
Cumulus announced the appointments on 16 September 2025.
Copyright 2025 Evernow Publishing Ltd.